All News
SLE Preview: abolishing refractory with CAR-T and better B-cell therapies
Inhibition of B cell activating factor (BAFF) and B cell depletion are the two most evaluated strategies over the last 15 years in the field of SLE therapeutics, with licensing of belimumab and off-label use of rituximab.
Read Article
Significant proportion of patients in PsA do not achieve remission across the domains. This can be due to disease heterogeneity, domain differences, comorbidities. There is a need to study the use of combination ts and bDMARDs. Difficult to Manage PsA session #EULAR2024 Ribeiro,… https://t.co/Wt3jgtIR9N https://t.co/VzCApikqek
Links:
Dr. Antoni Chan synovialjoints ( View Tweet)
Join us later for a some very exciting pieces of translational science across a AIRDs.
All these abstracts sharing one thing in common: tissue, tissue, tissue!
16:30-18:00 Room A8.2
@RheumNow #EULAR2024 https://t.co/HrHP5tmHDD
Aurelie Najm AurelieRheumo ( View Tweet)
Grappa - distinguish D2T from complex to manage - objective signs of inflammation imaging - US or MRI not lab markers @rheumnow #EULAR2024
Peter Nash drpnash ( View Tweet)
#EULAR2024 Eular Debate Showdown between @Janetbirdope vs @drdavidliew
Topic: can observational study debunk RCT?
This stemmed from Oral Surveillance = an increased risk of malignany & MACE with tofacitinib compared with TNF-i. Regulatories extrapolated to all JAK-i @RheumNow https://t.co/hg6xJZDHiA
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
The great debate on JAKi risk and special warnings
And who better than @RheumNow to keep score between @Janetbirdope & @drdavidliew
Get the popcorn ready 🍿
#EULAR2024 https://t.co/z50Ob8q0i0
Aurelie Najm AurelieRheumo ( View Tweet)
almost half PsA patients have 3 pr more co-morbidities and 67% of those surveyed do not think rheumos should not manage them - when did we stop being physicians ? @rheumnow #EULAR2024
Peter Nash drpnash ( View Tweet)
« difficult to treat PsA » how mich combination obesity, non-inflammatory MSK pain, fibromyalgia and depression making assessment tricky and risk of rattling through therapies fast! @rheumnow #EULAR2024
Peter Nash drpnash ( View Tweet)
Dr. D Aletaha defines The #EULARManifesto, "It is about patient centeredness-- improving quality of care, advocating for patients, timely access to specialists, pushing R&D innovation, integrating technology to make sure every patient gets the care they need." @rheumnow #EULAR24
TheDaoIndex KDAO2011 ( View Tweet)
🌎 Global disparities in steroid prescribing in #SLE
💊 HCQ assoc with decreased steroid use
📈 Other contributing factors may be prevalence, severity & phenotype of disease, plus access to DMARDs & biologics
📍SLE poster tour 15:30 TODAY
#EULAR2024
Abs #POS0013
@RheumNow https://t.co/7pL8kpeqOs
Mrinalini Dey DrMiniDey ( View Tweet)
LBA0001 (2024)
EFFICACY AND SAFETY OF UPADACITINIB IN PATIENTS WITH GIANT CELL ARTERITIS (SELECT-GCA): A DOUBLE-BLIND, RANDOMIZED CONTROLLED PHASE 3 TRIAL
- looking good, nice results @rheumnow #EULAR2024
Peter Nash drpnash ( View Tweet)
LONG-TERM EFFICACY TOCILIZUMAB AFTER ULTRA-SHORT GC TO TREAT GCA: 3 Yr FOLLOW-UP OF THE GUSTO TRIAL
3 day GC pulse immediate 12 mths Toci 85% drug free remission at 4 yrs! @rheumnow #EULAR2024
Peter Nash drpnash ( View Tweet)
RISK OF PsA IN PATIENTS WITH PsO UNDERGOING bDMARDs GLOBAL POPULATION STUDY (TRINETX)
870,000 PsO pts without PsA treated with bDMARDS - Il12/23i and Il23i. 30-37% lower PsA developed than comparators @rheumnow #EULAR2024
Peter Nash drpnash ( View Tweet)
OP0031 (2024)
COMPARATIVE ANALYSIS OF TNF INHIBITORS AND IL17 INHIBITORS IN PSORIATIC ARTHRITIS: EXPLORING CARDIOVASCULAR OUTCOMES signif absolute risk difference 3 % ischaemic heart disease 2 % heart failure TNFi vs IL17i @rheumnow #EULAR2024
Peter Nash drpnash ( View Tweet)
And were are on folks!! 🎙️
Delighted to join @RheumNow faculty again this year
I will be covering RA and PsA topics during #EULAR2024
Don’t miss our Daily recaps live 6pm
Oh and if you see me around, come and say Hi! https://t.co/TrQ9b3WeSy
Aurelie Najm AurelieRheumo ( View Tweet)
Grappa difficult to treat PsA meeting - SLR, Patient & rheumo survey, definition eg - fail 1 csDMARD & 2 bDMARDs different MOA - names matter suggest ditch « difficult » for « refractory » @rheumnow #EULAR2024
Peter Nash drpnash ( View Tweet)
Australian studyshows knee OA pts unconsciously believe that activity may be dangerous to their condition, despite medical advice telling them otherwise. 69% of people with knee pain had stronger implicit (unconscious) beliefs that exercise was dangerous https://t.co/iytfpcGvD8 https://t.co/N183ffYfPP
Links:
Dr. John Cush RheumNow ( View Tweet)
#EULAR2024 Opening Ceremony. @DanielAletaha highlighted values of @eular strategies that have been achieved:
Patient centredness ✔️
Innovation ✔️ - RheumaFacts, ENTRI, Exams
Inclusivity ✔️
To strive on 3 other values by next year under President-Elect @XBaraliakos @RheumNow https://t.co/wDR2vtv3I2
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
📄 #EULARAdvocacy Chair @carmona_loreto discusses the @eular_org manifesto at the #EULAR2024 opening ceremony
🔗You can read the full manifesto and find out more here: https://t.co/6CZuSYpiLl
@RheumNow https://t.co/DYcU9I6rmR
Mrinalini Dey DrMiniDey ( View Tweet)
« We must work together to achieve a future where RMDs are no longer an invisible problem »
Wise words from @carmona_loreto during Opening Plenary session #EULAR2024
@RheumNow
Aurelie Najm AurelieRheumo ( View Tweet)
